PL3016654T3 - Kwas tauroursodeoksycholowy (TUDCA) do zastosowania w leczeniu zaburzeń neurodegeneracyjnych - Google Patents
Kwas tauroursodeoksycholowy (TUDCA) do zastosowania w leczeniu zaburzeń neurodegeneracyjnychInfo
- Publication number
- PL3016654T3 PL3016654T3 PL13747521T PL13747521T PL3016654T3 PL 3016654 T3 PL3016654 T3 PL 3016654T3 PL 13747521 T PL13747521 T PL 13747521T PL 13747521 T PL13747521 T PL 13747521T PL 3016654 T3 PL3016654 T3 PL 3016654T3
- Authority
- PL
- Poland
- Prior art keywords
- tudca
- treatment
- neurodegenerative disorders
- tauroursodeoxycholic acid
- tauroursodeoxycholic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13747521.6A EP3016654B2 (en) | 2013-07-01 | 2013-07-01 | Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders |
| PCT/IB2013/055383 WO2015001379A1 (en) | 2013-07-01 | 2013-07-01 | Tauroursodeoxycholic acid (tudca) for use in the treatment of neurodegenerative disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL3016654T3 true PL3016654T3 (pl) | 2019-02-28 |
| PL3016654T5 PL3016654T5 (pl) | 2026-02-09 |
Family
ID=48949193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13747521.6T PL3016654T5 (pl) | 2013-07-01 | 2013-07-01 | Kwas tauroursodeoksycholowy (TUDCA) do zastosowania w leczeniu zaburzeń neurodegeneracyjnych |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3016654B2 (pl) |
| CN (2) | CN109999030A (pl) |
| CY (1) | CY1120835T1 (pl) |
| DK (1) | DK3016654T3 (pl) |
| ES (1) | ES2691408T5 (pl) |
| HR (1) | HRP20181554T4 (pl) |
| HU (1) | HUE040027T2 (pl) |
| LT (1) | LT3016654T (pl) |
| PL (1) | PL3016654T5 (pl) |
| PT (1) | PT3016654T (pl) |
| RS (1) | RS57763B1 (pl) |
| RU (1) | RU2016102092A (pl) |
| SI (1) | SI3016654T2 (pl) |
| SM (1) | SMT201800533T1 (pl) |
| TR (1) | TR201815345T4 (pl) |
| WO (1) | WO2015001379A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9872865B2 (en) | 2013-03-24 | 2018-01-23 | Amylyx Pharmaceuticals Inc. | Compositions for improving cell viability and methods of use thereof |
| IL293907A (en) * | 2019-12-16 | 2022-08-01 | Amylyx Pharmaceuticals Inc | Treatment of amyotrophic lateral sclerosis and related disorders |
| US11583542B2 (en) | 2019-12-16 | 2023-02-21 | Amylyx Pharmaceuticals, Inc. | Compositions of bile acids and phenylbutyrate compounds |
| JP7701931B2 (ja) * | 2020-02-13 | 2025-07-02 | プリレニア ニューロセラピューティクス リミテッド | プリドピジンおよび他の活性薬剤を使用して筋萎縮性側索を治療するための併用療法 |
| CN112972480A (zh) * | 2021-03-09 | 2021-06-18 | 兆科药业（广州）有限公司 | 一种含牛磺熊去氧胆酸、苯丁酸钠的复方散剂/颗粒剂、制备方法、用途以及其药物组合物 |
| US12138272B2 (en) | 2022-05-12 | 2024-11-12 | Amylyx Pharmaceuticals, Inc. | Methods and compositions for treating amyotrophic lateral sclerosis |
| CN120659782A (zh) * | 2023-02-15 | 2025-09-16 | 深圳君圣泰生物技术有限公司 | 小檗碱牛磺熊去氧胆酸盐组合物及其方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1770975A (zh) * | 2003-04-02 | 2006-05-10 | 明尼苏达大学评议会 | 提高细胞生存能力的方法 |
| ATE515288T1 (de) * | 2004-09-24 | 2011-07-15 | Rfe Pharma Llc | Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen |
| JP2008518935A (ja) * | 2004-11-01 | 2008-06-05 | セオ ホン ユー | 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物 |
| ES2358089T3 (es) * | 2004-11-01 | 2011-05-05 | Seo Hong Yoo | Métodos y composiciones para reducir la neurodegeneración en esclerosis lateral amiotrófica. |
| JP2008530100A (ja) | 2005-02-10 | 2008-08-07 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 視覚障害の治療方法 |
| WO2010008860A1 (en) | 2008-06-23 | 2010-01-21 | President And Fellows Of Harvard College | Modulation of neurodegenerative disease by modulating xbp-1 activity |
| EP2422787A1 (en) | 2010-08-17 | 2012-02-29 | Neurotec Pharma, S.L. | Diazoxide for use in the treatment of amyotrophic lateral sclerosis (als) |
-
2013
- 2013-07-01 HR HRP20181554TT patent/HRP20181554T4/hr unknown
- 2013-07-01 SI SI201331212T patent/SI3016654T2/sl unknown
- 2013-07-01 HU HUE13747521A patent/HUE040027T2/hu unknown
- 2013-07-01 CN CN201910097334.8A patent/CN109999030A/zh active Pending
- 2013-07-01 TR TR2018/15345T patent/TR201815345T4/tr unknown
- 2013-07-01 ES ES13747521T patent/ES2691408T5/es active Active
- 2013-07-01 EP EP13747521.6A patent/EP3016654B2/en active Active
- 2013-07-01 PL PL13747521.6T patent/PL3016654T5/pl unknown
- 2013-07-01 DK DK13747521.6T patent/DK3016654T3/en active
- 2013-07-01 WO PCT/IB2013/055383 patent/WO2015001379A1/en not_active Ceased
- 2013-07-01 SM SM20180533T patent/SMT201800533T1/it unknown
- 2013-07-01 PT PT13747521T patent/PT3016654T/pt unknown
- 2013-07-01 CN CN201380077879.3A patent/CN105358147A/zh active Pending
- 2013-07-01 RU RU2016102092A patent/RU2016102092A/ru unknown
- 2013-07-01 RS RS20181232A patent/RS57763B1/sr unknown
- 2013-07-01 LT LTEP13747521.6T patent/LT3016654T/lt unknown
-
2018
- 2018-10-17 CY CY181101065T patent/CY1120835T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016102092A (ru) | 2017-08-04 |
| EP3016654A1 (en) | 2016-05-11 |
| ES2691408T5 (en) | 2026-02-11 |
| HRP20181554T1 (hr) | 2018-12-14 |
| EP3016654B2 (en) | 2025-11-12 |
| RS57763B1 (sr) | 2018-12-31 |
| WO2015001379A1 (en) | 2015-01-08 |
| CY1120835T1 (el) | 2019-12-11 |
| CN109999030A (zh) | 2019-07-12 |
| PL3016654T5 (pl) | 2026-02-09 |
| SI3016654T2 (sl) | 2026-01-30 |
| LT3016654T (lt) | 2018-11-12 |
| DK3016654T3 (en) | 2018-11-05 |
| PT3016654T (pt) | 2018-11-09 |
| HUE040027T2 (hu) | 2019-02-28 |
| ES2691408T3 (es) | 2018-11-27 |
| SI3016654T1 (sl) | 2019-05-31 |
| SMT201800533T1 (it) | 2018-11-09 |
| HRP20181554T4 (hr) | 2026-03-27 |
| CN105358147A (zh) | 2016-02-24 |
| TR201815345T4 (tr) | 2018-11-21 |
| EP3016654B1 (en) | 2018-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3060252T3 (pl) | Zastosowanie cząsteczek wiążących semaforynę-4D do leczenia zaburzeń neurodegeneracyjnych | |
| HRP20181994T1 (hr) | Neuroaktivni steroidi i postupci za njihovu upotrebu | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| EP3068492A4 (en) | Neurodegenerative disorders and methods of treatment and diagnosis thereof | |
| PL3542798T3 (pl) | Aceklidyna do zastosowania w leczeniu starczowzroczności | |
| LT2961410T (lt) | Pirazolopirimidino darinių naudojimas gydant su pi3k susijusius sutrikimus | |
| IL241191A0 (en) | Local compositions and methods for treating local disorders | |
| SG11201509012QA (en) | Sobetirome in the treatment of myelination diseases | |
| DK2986624T3 (da) | Neuroaktive 19-nor-steroider til terapeutisk anvendelse | |
| PT2919796T (pt) | Utilização de akkermansia para o tratamento de distúrbios metabólicos | |
| DK2981269T3 (da) | Behandling af stofskifteforstyrrelser hos hestedyr | |
| LT3639828T (lt) | Deguoninių cholesterolio sulfatų (ocs) panaudojimas ūminio kepenų nepakankamumo gydymui | |
| PL2838539T3 (pl) | Składniki estrogenowe do zastosowania w leczeniu zaburzeń neurologicznych | |
| PL3466425T3 (pl) | Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych | |
| HRP20180337T1 (hr) | Kalcitonin mimetika za liječenje bolesti i poremećaja | |
| PL3016654T3 (pl) | Kwas tauroursodeoksycholowy (TUDCA) do zastosowania w leczeniu zaburzeń neurodegeneracyjnych | |
| EP3038707A4 (en) | Treatment of pediatric otic disorders | |
| ZA201603117B (en) | Withanolides useful for the treatment of neurodegenerative diseases | |
| DK3033350T3 (da) | Progesterone fosfatanaloger og anvendelser relateret dertil | |
| ZA201507724B (en) | The treatment of inflammatory disorders | |
| HUE045148T2 (hu) | Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére | |
| HUE048500T2 (hu) | Elõnedvesített törlõkendõk anális-rektális irritációk és rendellenességek kezelésére | |
| IL246148A0 (en) | Treating brain disorders and biomarkers related thereto | |
| EP2958570A4 (en) | THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS | |
| PT3370727T (pt) | Derivados da pregnenolona substituídos em c3 não bioconvertíveis para utilização no tratamento de distúrbios de toxicodependência |